Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Review · February 04, 2022

SGLT2 Inhibitors as Early Therapy for HFrEF

European Journal of Heart Failure


Additional Info

European Journal of Heart Failure
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction
Eur. J. Heart Fail 2021 Dec 10;[EPub Ahead of Print], D Tomasoni, GC Fonarow, M Adamo, SD Anker, J Butler, AJS Coats, G Filippatos, SJ Greene, TA McDonagh, P Ponikowski, G Rosano, P Seferovic, M Vaduganathan, AA Voors, M Metra

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading